Logo

American Heart Association

  23
  0


Final ID: TP242

Risk of symptomatic intracranial hemorrhage after mechanical thrombectomy in randomized clinical trials: A systematic review and meta-analysis

Abstract Body:
Background: Symptomatic intracranial hemorrhage (sICH) is the most dreaded complication after reperfusion therapy for acute ischemic stroke. We performed a meta-analysis of randomized controlled trials to estimate and compare risks of sICH after mechanical thrombectomy (MT) depending on the location of the large vessel occlusion, concomitant use of intravenous thrombolysis, timing of treatment, and core size.
Methods: Randomized controlled trials were included following a comprehensive search strategy on different databases from inception to March 1, 2024. Random-effect models in a meta-analysis were employed to get the pooled risk ratios (RRs) and their corresponding 95% confidence intervals (95% CI) for sICH with MT, compared to other reperfusion treatment regimens, including best medical treatment and intravenous thrombolysis (IVT).
Results: MT in the anterior circulation was associated with a significantly higher risk of sICH as compared with no-MT (RR: 1.46; 95%CI: 1.03-2.07; P = 0.037). Risk of sICH was comparable between the MT and MT+IVT groups (RR: 0.77; 95%CI: 0.57-1.03; P = 0.079). There was no difference in sICH risk with MT as compared with no-MT within 6 hours of last known well (RR: 1.14; 95%CI: 0.78-1.66; P = 0.485) and beyond that time (RR: 1.29; 95%CI: 0.80-2.08; P = 0.252); the risk of sICH was also comparable between MT conducted within 6 hours of last known well and MT conducted beyond that time (P = 0.512). The sICH risk for MT in the posterior circulation (RR: 7.48; 95%CI: 2.27-24.61) was significantly higher than for MT in the anterior circulation (RR: 1.18; 95%CI: 0.90-1.56) (P = 0.003). MT was also associated with a significantly higher sICH risk than no-MT among patients with large-core strokes (RR: 1.71; 95%CI: 1.09-2.66, P = 0.018).
Conclusion: When evaluating cumulative evidence from randomized controlled trials, the risk of sICH is increased after MT compared with patients not treated with MT. Yet, the difference is largely driven by the greater risk of sICH in patients treated with MT for posterior circulation occlusions and, to a lesser degree, large core strokes. Concomitant use of intravenous thrombolysis and the use of MT in the extended therapeutic window do not raise the risk of sICH.
  • Reda, Abdullah  ( Mayo Clinic, Rochester, MN, USA. , Rochester , Minnesota , United States )
  • Ghozy, Sherief  ( Mayo Clinic, Rochester, MN, USA. , Rochester , Minnesota , United States )
  • Gajjar, Aryan  ( Mayo Clinic, Rochester, MN, USA. , Rochester , Minnesota , United States )
  • Kallmes, David  ( Mayo Clinic, Rochester, MN, USA. , Rochester , Minnesota , United States )
  • Rabinstein, Alejandro  ( MAYO CLINIC NEUROLOGY , Rochester , Minnesota , United States )
  • Author Disclosures:
    Abdullah Reda: No Answer | Sherief Ghozy: DO NOT have relevant financial relationships | Aryan Gajjar: DO NOT have relevant financial relationships | David Kallmes: DO have relevant financial relationships ; Individual Stocks/Stock Options:Piraeus Medical:Active (exists now) ; Research Funding (PI or named investigator):Stryker:Past (completed) ; Research Funding (PI or named investigator):Medical Device Engineering:Active (exists now) ; Research Funding (PI or named investigator):Octapharma:Active (exists now) ; Research Funding (PI or named investigator):Sensome:Active (exists now) ; Research Funding (PI or named investigator):Cerenovus:Active (exists now) ; Ownership Interest:Superior Medical Editors:Active (exists now) ; Individual Stocks/Stock Options:Nested Knowledge:Active (exists now) ; Ownership Interest:Conway Medical:Active (exists now) | Alejandro Rabinstein: DO have relevant financial relationships ; Advisor:Chiesi:Past (completed) ; Other (please indicate in the box next to the company name):Boehringer Ingelheim (CEC member):Active (exists now) ; Other (please indicate in the box next to the company name):Boston Scientific (CEC member):Active (exists now) ; Advisor:Shionogi:Active (exists now) ; Advisor:Ceribell:Past (completed)
Meeting Info:
Session Info:

Neuroendovascular Posters II

Thursday, 02/06/2025 , 07:00PM - 07:30PM

Poster Abstract Session

More abstracts on this topic:
A First-in-Class Humanized Antibody Fragment Targeting Platelet Glycoprotein Ibα: A Comprehensive Preclinical Study of CA1001 for the Treatment of Acute Ischemic Stroke

Xu Xiaohong, Preeti Preeti, Yu Ruoying, Shaykhalishahi Hamed, Zhang Cheng, Shen Chuanbin, Li Bei, Tang Naping, Chang Yan, Xiang Qian, Cui Yimin, Lei Xi, Ni Heyu, Zhu Guangheng, Liu Zhenze, Hu Xudong, Slavkovic Sladjana, Neves Miguel, Ma Wenjing, Xie Huifang

Estimates of Long-term Social Isolation Among Patients with Intracerebral Hemorrhage

Borei Karim, Bako Abdulaziz, Pan Alan, Khan Osman, Vahidy Farhaan, Potter Thomas

More abstracts from these authors:
Can the clot meniscus and claw signs predict thrombectomy and clinical outcomes in stroke patients? A Systematic Review and Meta-Analysis

Reda Abdullah, Cortese Jonathan, Gajjar Aryan, Douri Dani, Ghozy Sherief, Kallmes David

Cardiac CT versus transesophageal and transthoracic echocardiography for intra-cardiac thrombus detection in ischemic stroke: A systematic review and meta-analysis of 43 studies

Ghozy Sherief, Liu Michael, Kobeissi Hassan, Abbas Alzhraa S., Kadirvel Ram, Rabinstein Alejandro, Kallmes David, Nasr Deena

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)